Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Thonburi Healthcare chairman resigns after market ban

Dr Boon Vanasin, the founder and chairman of Thonburi Healthcare Group (THG), is resigning from the company’s board as he faces a market ban in connection with claims he made last year about the purchase of Pfizer coronavirus vaccines.

Bangkok Post

Moderna sues Pfizer, BioNTech over COVID vaccine technology

Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their COVID-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.

Tribune News Service

Moderna sues Pfizer over Covid vaccine

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first Covid-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

Bangkok Post

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna sues Pfizer over patents behind COVID-19 vaccine

COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine

The Independent UK

Moderna sues Pfizer-BioNTech accusing them of copying Covid shot technology

‘We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission,’ Moderna legal officer says

The Independent UK

Is Pfizer a Buy Before New Omicron Boosters Roll Out?

Pharmaceutical giant Pfizer’s (PFE) omicron-targeted booster doses could soon be authorized this fall. The company has benefited largely from the pandemic and its vaccine rollouts. Now let’s find out if PFE is a Buy now as it prepares to roll out its booster doses….

StockNews.com

Moderna sues Pfizer, BioNTech over COVID-19 vaccine

The lawsuit seeks unspecified monetary damages for patent infringement.

Axios

Read news from The Economist, FT, and more,
with one subscription

Tweaked COVID boosters close but how much will they help?

COVID-19 vaccines tweaked to better match today’s omicron threat are expected to roll out in a few weeks but how much will they help

The Independent UK

How common is Paxlovid rebound as Jill Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK

Study: Pfizer COVID pill showed no benefit in younger adults

Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults

The Independent UK

How common is Paxlovid rebound as Jill Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK

A looming COVID risk in California? Schools return with fewer rules, lagging vaccine rates

LOS ANGELES — California schools reopened for the fall semester with loosened COVID-19 protocols and low student vaccination rates among younger children, presenting a new test for the trajectory of the pandemic as some experts expect another rise in cases when winter arrives.

Los Angeles Times

Pfizer COVID shots appear 73% effective in children under 5

Pfizer’s says its COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring

The Independent UK

What Are Whales Doing With Pfizer

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 10 strange trades.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Pfizer’s shot is 73% effective against COVID in children under 5

Pfizer Inc.’s COVID-19 vaccine was 73.2% effective against the disease in a trial of children 6 months through 4 years old, reinforcing results that led to the shot’s authorization in young kids in June.

Tribune News Service

Pfizer files application for booster against latest variants

Pfizer Inc. and BioNTech SE asked the U.S. to authorize a new COVID-19 booster shot customized against the currently circulating COVID-19 variants as governments race to protect their populations against the ever-mutating virus.

WEKU

Pfizer asks FDA to greenlight new omicron booster shots, which could arrive this fall

Pfizer has submitted data on its bivalent COVID-19 booster shot that specifically targets the latest omicron subvariants. If authorized, the company says the shots could be ready as soon as September.

The Independent UK

Pfizer seeks OK of updated COVID vaccine booster for fall

Pfizer has asked U.S. regulators to authorize its combination COVID-19 vaccine that adds protection against the newest omicron relatives

Get all your
news in one place.

100's of premium titles.
One news app.

Wales Online

Next phase of Covid jabs rollout starts next month

Around 26m people across England eligible for autumn booster

Bangkok Post

Covid vaccine plan for the very young

The government plans to buy 2.9 million doses of Covid-19 vaccine from Pfizer for children aged from six months to four years.

The Independent UK

Covid booster rollout of dual-strain jab to start on 5 September

Moderna’s new dual-strain vaccine will be offered to millions of Britons ahead of winter

WEKU

What's behind the FDA's controversial strategy for evaluating new COVID boosters

Some scientists are alarmed that the agency plans to evaluate the next generation of boosters by reviewing mouse studies alone. Others say there's no time to waste waiting for human trials.

Daily Mirror

All over-50s to get a new Covid jab targeted to protect against Omicron variant

Britain became the first country to approve a “bivalent” jab on Monday that directly targets Omicron and the original Covid-19 strain - as 29 million people will initially be invited for the vaccine

The Independent UK

‘No second-rate vaccines’ health chief insists as half will miss out on dual-strain booster

Roughly 29 million people are eligible for an autumn booster but there are just 13 million doses of the new bivalent Moderna jab available

StockNews.com

5 Income Stocks to Turn to When Times Are Tough

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

1 … 40 41 42 43

People

Taweesilp Visanuyothin

30 stories

Maggie Throup

19 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.